You are here: Industry Insights > Pfizer

News List

Sinopharm announces that Paxlovid from Pfizer is Available in China PharmaSources
March 01, 2023
China National Pharmaceutical Group (Sinopharm) announced that Paxlovid from Pfizer is allowed to introduce in China. Here is the news from Pharma Sources.
China approves use of Pfizer’s COVID drug Paxlovid ExpressPharma
February 15, 2022
It is not immediately clear if China is already in talks with Pfizer to procure the pill.
Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine ExpressPharma
February 15, 2022
This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific.
Pfizer and BioNTech to extend rolling submission for Covid-19 vaccine Pharmaceutical-Technology
February 15, 2022
Pfizer and BioNTech are set to extend their rolling submission to the US Food and Drug Administration (FDA) for amending the emergency use authorization (EUA) of the Covid-19 vaccine to include children aged six months to four years.
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development AmericanPharmaceuticalReview
February 15, 2022
CytoReason announced the extension of its collaboration agreement with Pfizer.
Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment FirstWordPharma
February 14, 2022
Singapore has received its first batch of Pfizer's oral COVID-19 treatment Paxlovid, after authorities last week said they had approved the tablet for COVID-19 in adults at risk for severe disease, reported CNA.
FDA Postpones Decision on Pfizer COVID-19 Vaccine for Under 5s drugs.com
February 11, 2022
The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting.
FDA Postpones Decision on Pfizer COVID Vaccine for Kids Under 5 drugs.com
February 11, 2022
The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting that was slated...
Pfizer reports 92% operational growth in full-year 2021 revenues Pharmaceutical-Technology
February 10, 2022
The company provided full year 2022 guidance for revenues in the range of $98bn to $102bn.
Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate WorldPharmaNews
February 07, 2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15.